Colestipol tablets in adolescents with familial hypercholesterolaemia

The objective of this study was to examine palatability and side effects of the new tablet formulation of colestipol. A clinical series of 23 boys and 4 girls aged 10-16 years with heterozygous familial hypercholesterolaemia were given 2-12 g colestipol daily for 6 months in an open study. There were no serious side effects. The median reduction in low density lipoprotein cholesterol level was 20%. All preferred the tablets to resin granules they had tried previously. We conclude that low-dose colestipol tablets appear to be safe and effective, and are preferred by adolescents.